Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00827112 · ClinicalTrials.gov registry record · Phase 2

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

A Phase 2 study of Human Immunodeficiency Virus-1, sponsored by ViiV Healthcare.

Completed
Registry status
Phase 2
Development phase
129
Enrollment target
20
Study locations

NCT00827112 is a Phase 2 study of Human Immunodeficiency Virus-1 that has completed, run by ViiV Healthcare. The registered enrollment target is 129 participants. The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00827112, a Phase 2 study of Human Immunodeficiency Virus-1, has completed, sponsored by ViiV Healthcare.

COMPLETED
Registry status
Phase 2
Development phase
129 participants
Enrollment target
20
Study locations

Study Summary

This is a pilot study to examine if the novel treatment regimen maraviroc plus boosted atazanavir can be expected to be safe and efficacious in treatment naive HIV infected patients. Based on the results from this study, a confirmatory phase 3 study may be conducted.

Interventions

  • DRUG maraviroc

Study Locations (20)

Florida

  • Pfizer Investigational Site - Miami
  • Pfizer Investigational Site - Miami
  • Pfizer Investigational Site - Miami
  • Pfizer Investigational Site - Orlando
  • Pfizer Investigational Site - Pensacola
  • Pfizer Investigational Site - St. Petersburg
  • Pfizer Investigational Site - Tampa
  • Pfizer Investigational Site - Tampa

California

  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Los Angeles

Massachusetts

  • Pfizer Investigational Site - Springfield
  • Pfizer Investigational Site - Springfield

Connecticut

  • Pfizer Investigational Site - Norwalk

District of Columbia

  • Pfizer Investigational Site - Washington D.C.

Georgia

  • Pfizer Investigational Site - Atlanta

Illinois

  • Pfizer Investigational Site - Chicago

Michigan

  • Pfizer Investigational Site - Ann Arbor

Trial Details

FieldValue
Enrollment Target 129 participants
Start Date 2009-03
Est. Completion 2011-07
Phase Phase 2

Sponsor

ViiV Healthcare

182 total trials

What the Registry Record Tells You About NCT00827112

The ClinicalTrials.gov registry entry for NCT00827112 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Human Immunodeficiency Virus-1 appearing as the primary indexed condition, and to 1 intervention - of which maraviroc is the first listed.

NCT00827112 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00827112 about?

NCT00827112 is a clinical study titled "A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients". This is a pilot study to examine if the novel treatment regimen maraviroc plus boosted atazanavir can be expected to be safe and efficacious in treatment naive HIV infected patients. Based on the results from this study, a confirmatory phase 3 study may be conducted.

What is the current status of trial NCT00827112?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2009-03. Estimated completion is 2011-07.

What conditions does trial NCT00827112 study?

This clinical trial studies the following conditions: Human Immunodeficiency Virus-1.

What interventions are being tested in trial NCT00827112?

The interventions under investigation include: maraviroc (DRUG).

Who is sponsoring clinical trial NCT00827112?

This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00827112 being conducted?

This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.